Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma
about
Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challengesIn silico analysis reveals sequential interactions and protein conformational changes during the binding of chemokine CXCL-8 to its receptor CXCR1Leu128(3.43) (l128) and Val247(6.40) (V247) of CXCR1 are critical amino acid residues for g protein coupling and receptor activation.The emerging role of CXC chemokines and their receptors in cancer.Peptides derived from CXCL8 based on in silico analysis inhibit CXCL8 interactions with its receptor CXCR1.International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma.Molecular biology of normal melanocytes and melanoma cells.Inflammatory microenvironment and expression of chemokines in hepatocellular carcinomaLadarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment.The role of CXCR2 chemokine receptors in the oral squamous cell carcinoma.Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer.Chemokine CXCL1 may serve as a potential molecular target for hepatocellular carcinoma.Editorial: ADAMs control inflammation from afarHigh expression of CXCR2 is associated with tumorigenesis, progression, and prognosis of laryngeal squamous cell carcinoma.Chemokine (C-X-C motif) ligand 1 is a myokine induced by palmitate and is required for myogenesis in mouse satellite cells.NRAS destines tumor cells to the lungs.Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers
P2860
Q26866236-8CEBC9C5-30B8-47F8-95B7-A19E6679294DQ28542001-7C180CE8-1943-4D05-A6C9-5A263D5273F0Q31088115-1F6B9D77-1087-4B77-A706-1C344C191D57Q34263645-CC44AF11-C068-4957-9C24-977FCBBE473EQ36392735-68940E54-B8D3-4475-8646-27079D816967Q37432097-CFFEBD79-1F6B-449C-A252-7430209678CCQ37801939-0569E297-7337-4ADB-AB7D-7FCE1132D71EQ38092784-D106C40A-9534-4943-8270-74731D5CED97Q38878644-3764CE1D-92E6-4A6D-8677-BE2E1C8BEC86Q38994985-875AD81E-7BE7-4022-9772-FE3F9AB57E58Q39525081-7B841598-1375-4D71-9E9C-F3EAC3287DCCQ41472206-F5FFB9E3-E404-4AAE-817D-C04AAC9A7F21Q41601067-22D25A49-C26C-4069-9329-A1E70C683CDEQ42336258-1338C969-6C46-4CA8-BCC9-2FF9590F7894Q43580944-691DBDE4-FC5F-4F68-BFAF-8202764467A6Q46299056-B1829C89-18DA-47F4-9D73-B6E9BA9AEBE7Q47161788-96E93AEC-CEDB-4E12-8E7F-7E0615DBC0DBQ58694964-F61F7736-7FD2-4247-A0A0-B6A2AE02A40C
P2860
Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma
@ast
Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma
@en
Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma
@nl
type
label
Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma
@ast
Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma
@en
Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma
@nl
prefLabel
Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma
@ast
Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma
@en
Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma
@nl
P2093
P2860
P3181
P1476
Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma
@en
P2093
Bhawna Sharma
Michelle L Varney
Rakesh K Singh
Seema Singh
P2860
P304
P3181
P356
10.1517/14728221003652471
P407
P577
2010-04-01T00:00:00Z